Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasm Metastasis 2 Sarcoma, Ewing 1 Sarcoma 1 Rhabdomyosarcoma 1 Rectal Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pancreatic Neoplasms 1 Neuroblastoma 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Melanoma 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma 1 Leukemia, Myeloid, Acute 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Hodgkin Disease 1 Gastro-enteropancreatic neuroendocrine tumor 1 Colonic Neoplasms 1 Carcinoma, Islet Cell 1 Breast Neoplasms 1

Interventions

pembrolizumab 300 Nivolumab 273 Ipilimumab 250 aldesleukin 137 Cyclophosphamide 136 Interleukin-2 105 trametinib 82 dabrafenib 76 Temozolomide 75 Dacarbazine 74 Vemurafenib 71 fludarabine 68 fludarabine phosphate 62 Biopsy 49 binimetinib 47 sargramostim 44 Radiosurgery 44 Bevacizumab 43 Paclitaxel 42 encorafenib 40 incomplete Freund's adjuvant 39 atezolizumab 38 Radiotherapy 37 Specimen Handling 36 Cisplatin 36 CTLA-4 Antigen 36 Magnetic Resonance Spectroscopy 35 Carboplatin 35 cobimetinib 34 Introns 33

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Melanoma × Cytokines × Clear all

NCT02350972 2015-01-30

Inducing Systemic Immunity and Regressions in Metastatic Melanoma

NYU Langone Health

Phase 1 Completed

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡